Alnylam Pharmaceuticals | ALNY - Capital Social e Reservas





Capital Social e Reservas Alterar Data
Acadia Pharmaceuticals USD 1.25B 20.68M 2026-03
Agios Pharmaceuticals USD 1.11B 84M 2026-03
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Amgen USD 9.19B 532M 2026-03
Arrowhead Research USD 613.98M 45.56M 2026-03
BioCryst Pharmaceuticals USD -553.84M 434.69M 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Incyte USD 5.62B 455.37M 2026-03
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
Moderna USD 7.41B 1.24B 2026-03
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Novartis USD 46.13B 1.8B 2025-12
PTC Therapeutics USD -180.46M 24.85M 2026-03
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 71.71B 14.25B 2025-12
Sarepta Therapeutics USD 1.51B 364.48M 2026-03
Takeda JPY 7.77T 129.5B 2026-03
Tectonic Therapeutic USD 230.42M 20.91M 2026-03
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03
Xencor USD 515.63M 119.95M 2026-03